Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9915
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYap, Kelvin Ken
dc.contributor.authorByrne, Amanda Jen
dc.contributor.authorBerlangieri, Salvatore Uen
dc.contributor.authorPoon, Aurora M Ten
dc.contributor.authorMitchell, Paul L Ren
dc.contributor.authorKnight, Simon Ren
dc.contributor.authorClarke, Peter Cen
dc.contributor.authorHarris, Anthony Hen
dc.contributor.authorTauro, Andrewen
dc.contributor.authorRowe, Christopher Cen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:11:58Z
dc.date.available2015-05-15T23:11:58Z
dc.date.issued2005-05-05en
dc.identifier.citationEuropean Journal of Nuclear Medicine and Molecular Imaging 2005; 32(9): 1033-40en
dc.identifier.govdoc15875178en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9915en
dc.description.abstract(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging is an important staging procedure in patients with non-small cell lung cancer (NSCLC). We aimed to demonstrate, through a decision tree model and the incorporation of real costs of each component, that routine FDG-PET imaging as a prelude to curative surgery will reduce requirements for routine mediastinoscopy and overall hospital costs.A decision tree model comparing routine whole-body FDG-PET imaging to routine staging mediastinoscopy was used, with baseline variables of sensitivity, specificity and prevalence of non-operable and metastatic disease obtained from institutional data and a literature review. Costings for hospital admissions for mediastinoscopy and thoracotomy of actual patients with NSCLC were determined. The overall and average cost of managing patients was then calculated over a range of FDG-PET costs to derive projected cost savings to the community.The prevalence of histologically proven mediastinal involvement in patients with NSCLC presenting for surgical assessment at our institution is 20%, and the prevalence of distant metastatic disease is 6%. Based on literature review, the pooled sensitivity and specificity of FDG-PET for detection of mediastinal spread are 84% and 89% respectively, and for mediastinoscopy, 81% and 100%. The average cost of mediastinoscopy for NSCLC in our institution is 4,160 AUD, while that of thoracotomy is 15,642 AUD. The cost of an FDG-PET scan is estimated to be 1,500 AUD. Using these figures and the decision tree model, the average cost saving is 2,128 AUDper patient.Routine FDG-PET scanning with selective mediastinoscopy will save 2,128 AUD per patient and will potentially reduce inappropriate surgery. These cost savings remain robust over a wide range of disease prevalence and FDG-PET costs.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAustraliaen
dc.subject.otherCarcinoma, Non-Small-Cell Lung.economics.pathology.radionuclide imaging.surgeryen
dc.subject.otherCost-Benefit Analysisen
dc.subject.otherDecision Support Systems, Clinicalen
dc.subject.otherFemaleen
dc.subject.otherHealth Care Costs.statistics & numerical dataen
dc.subject.otherHumansen
dc.subject.otherLength of Stay.economicsen
dc.subject.otherLung Neoplasms.economics.pathology.radionuclide imaging.surgeryen
dc.subject.otherMaleen
dc.subject.otherMediastinoscopy.economicsen
dc.subject.otherMiddle Ageden
dc.subject.otherModels, Economicen
dc.subject.otherNeoplasm Staging.economicsen
dc.subject.otherPositron-Emission Tomography.economicsen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTreatment Outcomeen
dc.titlePositron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of nuclear medicine and molecular imagingen
dc.identifier.affiliationCentre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australiaen
dc.identifier.doi10.1007/s00259-005-1821-0en
dc.description.pages1033-40en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15875178en
dc.type.austinJournal Articleen
local.name.researcherBerlangieri, Salvatore U
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
15875178.pdf58.2 kBAdobe PDFView/Open
Show simple item record

Page view(s)

36
checked on Mar 28, 2024

Download(s)

70
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.